Teladoc Health (TDOC) EBITDA (2014 - 2026)

Teladoc Health has disclosed EBITDA across 13 years of filings, most recently posting -$64.5 million for Q1 2026.

• EBITDA for Q1 2026 came in at -$64.5 million, up 29.76% year-over-year; the trailing twelve-month figure through Mar 2026 was -$169.3 million (up 83.25% YoY), and the FY2025 annual result was -$196.7 million, up 80.39% from the prior year.
• EBITDA came in at -$64.5 million for Q1 2026 at Teladoc Health, down from -$25.3 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$24.4 million in Q4 2023 to a low of -$6.7 billion in Q1 2022.
• The 5-year median for EBITDA is -$64.5 million (2026), against an average of -$892.6 million.
• Across the five-year window, EBITDA slumped 23469.1% in 2022 and soared 99.36% in 2023, its largest moves.
• Teladoc Health's EBITDA stood at -$3.8 billion in 2022, then jumped by 99.36% to -$24.4 million in 2023, then tumbled by 103.99% to -$49.7 million in 2024, then jumped by 49.16% to -$25.3 million in 2025, then plunged by 155.43% to -$64.5 million in 2026.
• The last three EBITDA figures came in at -$64.5 million (Q1 2026), -$25.3 million (Q4 2025), and -$48.7 million (Q3 2025), per Business Quant data.